|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jeong Y, Xie Y, Lee W, Bookout AL, Girard
L, Raso G, Behrens C, Wistuba II, Gadzar AF, Minna JD and
Mangelsdorf DJ: Research resource: Diagnostic and therapeutic
potential of nuclear receptor expression in lung cancer. Mol
Endocrinol. 26:1443–1454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mukohara T, Engelman JA, Hanna NH, Yeap
BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z,
Cantley LC, et al: Differential effects of gefitinib and cetuximab
on non-small-cell lung cancers bearing epidermal growth factor
receptor mutations. J Natl Cancer Ins. 97:1185–1194. 2005.
View Article : Google Scholar
|
|
4
|
Amann J, Kalyankrishna S, Massion PP, Ohm
JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Salmon
Stuart J, et al: Aberrant epidermal growth factor receptor
signaling and enhanced sensitivity to EGFR inhibitors in lung
cancer. Cancer Res. 65:226–235. 2005.PubMed/NCBI
|
|
5
|
Soria JC, Mok TS, Cappuzzo F and Jänne PA:
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current
trends and future prospects. Cancer Treat Rev. 38:416–430. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nguyen KS and Neal JW: First-line
treatment of EGFR-mutant non-small-cell lung cancer: The role of
erlotinib and other tyrosine kinase inhibitors. Biologics.
6:337–345. 2012.PubMed/NCBI
|
|
7
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nature
Med. 19:1389–1400. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gong H, Guo P, Zhai Y, Zhou J, Uppal H,
Jarzynka MJ, Song WC, Cheng SY and Xie W: Estrogen deprivation and
inhibition of breast cancer growth in vivo through activation of
the orphan nuclear receptor liver X receptor. Mol Endocrinol.
21:1781–1790. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vedin LL, Lewandowski SA, Parini P,
Gustafsson JA and Steffensen KR: The oxysterol receptor LXR
inhibits proliferation of human breast cancer cells.
Carcinogenesis. 30:575–579. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Villablanca EJ, Raccosta L, Zhou D,
Fontana R, Maggioni D, Negro A, Sanvito F, Ponzoni M, Valentinis B,
Bregni M, et al: Tumor-mediated liver X receptor-alpha activation
inhibits CC chemokine receptor-7 expression on dendritic cells and
dampens antitumor responses. Nat Med. 16:98–105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scoles DR, Xu X, Wang H, Tran H,
Taylor-Harding B, Li A and Karlan BY: Liver X receptor agonist
inhibits proliferation of ovarian carcinoma cells stimulated by
oxidized low density lipoprotein. Gynecol Oncol. 116:109–116. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lo Sasso G, Bovenga F, Murzilli S,
Salvatore L, Di Tullio G, Martelli N, D'Orazio A, Rainaldi S, Vacca
M, Mangia A, et al: Liver X receptors inhibit proliferation of
human colorectal cancer cells and growth of intestinal tumors in
mice. Gastroenterology. 144(1497–1507): e1–e13. 2013.
|
|
13
|
Bischoff ED, Daige CL, Petrowski M, Dedman
H, Pattison J, Juliano J, Li AC and Schulman IG: Non-redundant
roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in
low density lipoprotein receptor knockout mice. J Lipid Res.
51:900–906. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chuu CP and Lin HP: Antiproliferative
effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on
multiple human cancer cell lines. Anticancer Res. 30:3643–3648.
2010.PubMed/NCBI
|
|
15
|
Wairagu PM, Park KH, Kim J, Choi JW, Kim
HW, Yeh BI, Jung SH, Yong SJ and Jeong Y: Combined therapeutic
potential of nuclear receptors with receptor tyrosine kinase
inhibitors in lung cancer. Biochem Biophys Res Commun. 447:490–495.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morgillo F, Cascone T, D'Aiuto E,
Martinelli E, Troiani T, Saintigny P, De Palma R, Heymach JV,
Berrino L, Tuccillo C and Ciardiello F: Antitumour efficacy of MEK
inhibitors in human lung cancer cells and their derivatives with
acquired resistance to different tyrosine kinase inhibitors. Br J
Cancer. 105:382–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu X, Xing L, Jiao Y, Xu J, Wang X, Han A
and Yu J: BTG2 overexpression increases the radiosensitivity of
breast cancer cells in vitro and in vivo. Oncology Res. 20:457–465.
2013. View Article : Google Scholar
|
|
19
|
Harada D, Takigawa N, Ochi N, Ninomiya T,
Yasugi M, Kubo T, Takeda H, Ichihara E, Ohashi K, Takata S, et al:
JAK2-related pathway induces acquired erlotinib resistance in lung
cancer cells harboring an epidermal growth factor
receptor-activating mutation. Cancer Sci. 103:1795–1802. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nguyen KS, Kobayashi S and Costa DB:
Acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small-cell lung cancers dependent on the
epidermal growth factor receptor pathway. Clin Lung Cancer.
10:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suda K, Tomizawa K, Osada H, Maehara Y,
Yatabe Y, Sekido Y and Mitsudomi T: Conversion from the ‘oncogene
addiction’ to ‘drug addiction’ by intensive inhibition of the EGFR
and MET in lung cancer with activating EGFR mutation. Lung Cancer.
76:292–299. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Derangère V, Chevriaux A, Courtaut F,
Bruchard M, Berger H, Chalmin F, Causse SZ, Limagne E, Végran F,
Ladoire S, et al: Liver X receptor β activation induces pyroptosis
of human and murine colon cancer cells. Cell Death Differ.
21:1914–1924. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herr I and Debatin KM: Cellular stress
response and apoptosis in cancer therapy. Blood. 98:2603–2614.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu Y, Yu DD, Yan DL, Hu Y, Chen D, Liu Y,
Zhang HD, Yu SR, Cao HX and Feng JF: Liver X receptor as a drug
target for the treatment of breast cancer. Anticancer Drugs.
27:373–382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mitro N, Vargas L, Romeo R, Koder A and
Saez E: T0901317 is a potent PXR ligand: Implications for the
biology ascribed to LXR. FEBS Lett. 581:1721–1726. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Collins JL, Fivush AM, Watson MA, Galardi
CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, et
al: Identification of a nonsteroidal liver X receptor agonist
through parallel array synthesis of tertiary amines. J Med Chem.
45:1963–1966. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Courtaut F, Derangère V, Chevriaux A,
Ladoire S, Cotte AK, Arnould L, Boidot R, Rialland M, Ghiringhelli
F and Rébé C: Liver X receptor ligand cytotoxicity in colon cancer
cells and not in normal colon epithelial cells depends on LXRβ
subcellular localization. Oncotarget. 6:26651–26662. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gabitova L, Restifo D, Gorin A, Manocha K,
Handorf E, Yang DH, Cai KQ, Klein-Szanto AJ, Cunningham D, Kratz
LE, et al: Endogenous sterol metabolites regulate growth of
EGFR/KRAS-dependent tumors via LXR. Cell Rep. 12:1927–1938. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cadranel J, Ruppert AM, Beau-Faller M and
Wislez M: Therapeutic strategy for advanced EGFR mutant
non-small-cell lung carcinoma. Crit Rev Oncol Hematol. 88:477–493.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Engelman JA and Jänne PA: Mechanisms of
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small cell lung cancer. Clin Cancer Res.
14:2895–2899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Turke AB, Zejnullahu K, Wu YL, Song Y,
Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L,
et al: Preexistence and clonal selection of MET amplification in
EGFR mutant NSCLC. Cancer Cell. 17:77–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bivona TG, Hieronymus H, Parker J, Chang
K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, et
al: FAS and NF-κB signalling modulate dependence of lung cancers on
mutant EGFR. Nature. 471:523–526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sakuma Y, Yamazaki Y, Nakamura Y,
Yoshihara M, Matsukuma S, Koizume S and Miyagi Y: NF-κB signaling
is activated and confers resistance to apoptosis in
three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.
Biochem Biophys Res Commun. 423:667–671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo D, Reinitz F, Youssef M, Hong C,
Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, et al:
An LXR agonist promotes glioblastoma cell death through inhibition
of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov.
1:442–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng O, Ostrowski RP, Liu W and Zhang JH:
Activation of liver X receptor reduces global ischemic brain injury
by reduction of nuclear factor-kappaB. Neuroscience. 166:1101–1109.
2010. View Article : Google Scholar : PubMed/NCBI
|
